Needham Maintains Buy on Biogen, Raises Price Target to $323
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia maintains a Buy rating on Biogen (NASDAQ:BIIB) and raises the price target from $320 to $323.
July 26, 2023 | 10:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst maintains a Buy rating on Biogen and raises the price target to $323.
The raised price target by Needham analyst indicates a positive outlook for Biogen. This could potentially lead to an increase in the stock price in the short term as it signals the analyst's confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100